Literature DB >> 26770559

Genetic polymorphisms in the androgen metabolism pathway and risk of prostate cancer in low incidence Malaysian ethnic groups.

Prevathe Poniah1, Zahurin Mohamed2, Yamunah Devi Apalasamy2, Shamsul Mohd Zain2, Shanggar Kuppusamy1, Azad Ha Razack1.   

Abstract

Androgens are involved in prostate cancer (PCa) cell growth. Genes involved in androgen metabolism mediate key steps in sex steroid metabolism. This study attempted to investigate whether single nucleotide polymorphisms (SNPs) in the androgen metabolism pathway are associated with PCa risk in low incidence Asian ethnic groups. We genotyped 172 Malaysian subjects for cytochrome P450 family 17 (CYP17A1), steroid-5-alpha-reductase, polypeptide 1 and 2 (SRD5A1 and SRD5A2), and insulin-like growth factor 1 (IGF-1) genes of the androgen metabolism pathway and assessed the testosterone, dihydrotestosterone and IGF-1 levels. SNPs in the CYP17A1, SRD5A1, SRD5A2, and IGF-1 genes were genotyped using real-time polymerase chain reaction. Although we did not find significant association between SNPs analysed in this study with PCa risk, we observed however, significant association between androgen levels and the IGF-1 and several SNPs. Men carrying the GG genotype for SNP rs1004467 (CYP17A1) had significantly elevated testosterone (P = 0.012) and dihydrotestosterone (DHT) levels (P = 0.024) as compared to carriers of the A allele. The rs518673 of the SRD5A1 was associated with prostate specific antigen (PSA) levels. Our findings suggest CYP17A1 rs1004467 SNP is associated with testosterone and DHT levels indicating the importance of this gene in influencing androgen levels in the circulatory system of PCa patients, hence could be used as a potential marker in PCa assessment.

Entities:  

Keywords:  Prostate cancer; androgen; dihydrotestosterone; insulin-like growth factor 1; single nucleotide polymorphism; testosterone

Year:  2015        PMID: 26770559      PMCID: PMC4694459     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  45 in total

1.  Implications for prostate cancer of insulin-like growth factor-I (IGF-I) genetic variation and circulating IGF-I levels.

Authors:  Mattias Johansson; James D McKay; Fredrik Wiklund; Sabina Rinaldi; Martijn Verheus; Carla H van Gils; Göran Hallmans; Katarina Bälter; Hans-Olov Adami; Henrik Grönberg; Pär Stattin; Rudolf Kaaks
Journal:  J Clin Endocrinol Metab       Date:  2007-10-02       Impact factor: 5.958

2.  Serum insulin-like growth factor-I levels and prostate cancer risk--interpreting the evidence.

Authors:  P Cohen
Journal:  J Natl Cancer Inst       Date:  1998-06-17       Impact factor: 13.506

3.  A2 allele polymorphism of the CYP17 gene and prostate cancer risk in an iranian population.

Authors:  Arezu Karimpur-Zahmatkesh; Farah Farzaneh; Farkhondeh Pouresmaeili; Jalil Hosseini; Eznollah Azarghashb; Mohammad Yaghoobi
Journal:  Asian Pac J Cancer Prev       Date:  2013

4.  SRD5A polymorphisms and biochemical failure after radical prostatectomy.

Authors:  Etienne Audet-Walsh; Judith Bellemare; Geneviève Nadeau; Louis Lacombe; Yves Fradet; Vincent Fradet; Shu-Pin Huang; Bo-Ying Bao; Pierre Douville; Hugo Girard; Chantal Guillemette; Eric Lévesque
Journal:  Eur Urol       Date:  2011-06-29       Impact factor: 20.096

5.  Correlation of the osteoblastic phenotype with prostate-specific antigen expression in metastatic prostate cancer: implications for paracrine growth.

Authors:  A Doherty; G Smith; L Banks; T Christmas; R J Epstein
Journal:  J Pathol       Date:  1999-07       Impact factor: 7.996

Review 6.  The control of prostate-specific antigen expression and gene regulation by pharmacological agents.

Authors:  S C Dixon; K B Knopf; W D Figg
Journal:  Pharmacol Rev       Date:  2001-03       Impact factor: 25.468

7.  CYP17 gene polymorphism and its association in north Indian prostate cancer patients.

Authors:  Ranbir Chander Sobti; Lipsy Gupta; Hitender Thakur; Amlesh Seth; Sharwan K Singh; Pushpinder Kaur
Journal:  Anticancer Res       Date:  2009-05       Impact factor: 2.480

8.  IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Authors:  Jocelyn M Weiss; Wen-Yi Huang; Sabina Rinaldi; Thomas R Fears; Nilanjan Chatterjee; David Chia; E David Crawford; Rudolf Kaaks; Richard B Hayes
Journal:  Int J Cancer       Date:  2007-11-15       Impact factor: 7.396

9.  Importance of 5α-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer.

Authors:  Éric Lévesque; Isabelle Laverdière; Louis Lacombe; Patrick Caron; Mélanie Rouleau; Véronique Turcotte; Bernard Têtu; Yves Fradet; Chantal Guillemette
Journal:  Clin Cancer Res       Date:  2013-11-25       Impact factor: 12.531

Review 10.  Epidemiology of prostate cancer in the Asia-Pacific region.

Authors:  Peter D Baade; Danny R Youlden; Susanna M Cramb; Jeff Dunn; Robert A Gardiner
Journal:  Prostate Int       Date:  2013-06-30
View more
  3 in total

Review 1.  Oxidative stress in prostate hyperplasia and carcinogenesis.

Authors:  Udensi K Udensi; Paul B Tchounwou
Journal:  J Exp Clin Cancer Res       Date:  2016-09-08

2.  Associations Between Cytochrome P450 (CYP) Gene Single-Nucleotide Polymorphisms and Second-to-Fourth Digit Ratio in Chinese University Students.

Authors:  Jing Zhang; Mengyi Yang; Pengfei Luan; Wei Jia; Qiujun Liu; Zhanbing Ma; Jie Dang; Hong Lu; Qian Ma; Yanfeng Wang; Chunlan Mu; Zhenghao Huo
Journal:  Med Sci Monit       Date:  2021-03-16

3.  Association between polymorphisms in sex hormones synthesis and metabolism and prostate cancer aggressiveness.

Authors:  Inmaculada Robles-Fernandez; Luis Javier Martinez-Gonzalez; Manrique Pascual-Geler; Jose Manuel Cozar; Ignacio Puche-Sanz; Maria Jose Serrano; Jose Antonio Lorente; Maria Jesus Alvarez-Cubero
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.